Skip to main content

Table 3 PK parameters of AD16 in MAD groups

From: Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer’s disease: a randomized phase 1 study

PK parameters

30 mg

N = 8

40 mg

N = 8

Tmax,ss (h)

0.62 (0.33–1.00)

0.88 (0.50–4.00)

T1/2,ss (h)

7.24 ± 1.35 (18.69)

8.50 ± 1.63 (19.15)

Cmax,ss (ng/mL)

1127.38 ± 205.57 (18.23)

1528.75 ± 320.96 (20.99)

Cavg,ss (ng/mL)

478.59 ± 100.65 (21.03)

782.98 ± 127.79 (16.32)

Cmin,ss (ng/mL)

204.88 ± 73.91 (36.08)

449.63 ± 85.91 (19.11)

AUC0-τ,ss (h*ng/mL)

5743.12 ± 1207.85 (21.03)

9395.79 ± 1533.46 (16.32)

AUC0-48 h,ss (h*ng/mL)

8282.70 ± 2266.75 (27.37)

14,737.31 ± 3178.18 (21.57)

AUC0-∞,ss (h*ng/mL)

8377.29 ± 2338.26 (27.91)

15,061.14 ± 3425.91 (22.75)

CL/F,ss (mL/h)

5444.94 ± 1210.19 (22.23)

4353.55 ± 679.42 (15.61)

Vd/F,ss (mL)

55,625.89 ± 10,662.74 (19.17)

52,688.80 ± 9545.88 (18.12)

Rac,ss (%)

1.36 ± 0.24 (17.81)

1.68 ± 0.19 (11.12)

DF (%)

198.09 ± 50.69 (25.59)

137.29 ± 23.01 (16.76)

  1. Data are expressed as mean ± SD (CV%) unless otherwise specified. Tmax,ss (h) is expressed as median (range)